CVC‐related thrombosis ( · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in CVC‐related thrombosis ( compared with control (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in symptomatic CVC‐related thrombosis ( compared with control (low certainty).
1 finding from 1 review
Asymptomatic CVC‐related thrombosis ( · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in asymptomatic CVC‐related thrombosis ( compared with control (low certainty).
1 finding from 1 review
Major bleeding · children with a CVC
Does low molecular weight heparin prevent central venous… showed no clear difference in major bleeding ( compared with control (low certainty).
1 finding from 1 review
Minor bleeding · children with a CVC
1 finding from 1 review
Death during study period · children with a CVC
1 finding from 1 review
Total VTE · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All cause mortality · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality during hospital stay · people with critical limb ischaemia
1 finding from 1 review
Rate of amputation · people with critical limb ischaemia
It is very uncertain whether high cell dose changes amputation rate Assessed during in‐patient stay (Losordo 2012) compared with low cell dose (very low certainty).
1 finding from 1 review
Ulcer healing · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rest‐pain relief · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major VTE events bilateral ascending venography1 · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in major VTE events bilateral ascending venography1 compared with low molecular weight heparins (low certainty).
1 finding from 1 review
All‐cause Mortality events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors probably leads to higher all‐cause Mortality events compared with low molecular weight heparins (moderate certainty).
1 finding from 1 review
Total Bleeding events · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in total Bleeding events compared with low molecular weight heparins (low certainty).
1 finding from 1 review
ALT >3 times the upper normal limit · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors may leads to lower ALT >3 times the upper normal limit compared with low molecular weight heparins (low certainty).
1 finding from 1 review